AxoGen, Inc. to Participate at the 28th Annual ROTH Growth Conference

Share Article

Karen Zaderej, AxoGen CEO, to Present on Monday, March 14

AxoGen Logo

AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced that Karen Zaderej, President and Chief Executive Officer, is scheduled to present at the 28th Annual ROTH Conference on Monday, March 14, 2016 at 4:30pm PT (7:30pm ET) in Dana Point, California.

A live webcast and subsequent archived replay of the Company’s presentation may be accessed via the investor relations section of the Company’s website.

About AxoGen, Inc.

AxoGen (NASDAQ: AXGN) is a leading medical technology company dedicated to peripheral nerve repair. AxoGen’s portfolio of regenerative medicine products is available in the United States, Canada and several other countries and includes Avance® Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (“ECM”) coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. For more information about AxoGen or to sign up for news alerts, please visit http://www.AxoGenInc.com.

Contact:
AxoGen, Inc.
Peter J. Mariani, Chief Financial Officer
386.462.6856
InvestorRelations(at)AxoGenInc(dot)com

EVC Group
Michael Polyviou/Doug Sherk – Investor Relations            
212.850.6020/415.652.9100
mpolyviou(at)evcgroup.com; dsherk(at)evcgroup(dot)com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michael Polyviou/Doug Sherk - Investor Relations
EVC Group
+1 212.850.6020
Email >
Visit website